Verrica Pharmaceuticals, Inc.
https://verrica.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Verrica Pharmaceuticals, Inc.
Verrica’s Anticancer Efforts Kick Off With Promising Early Phase II BCC Data
The US firm’s oncolytic peptide candidate, VP-315, has shown tumor clearance in a Phase II basal cell carcinoma trial, marking a positive start for its plans to expand from non-malignant dermatology to skin cancer.
Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success
Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.
Supplemental Filings: Ycanth Approved For Molluscum; CDER Counter-Terrorism Head Retires; 5 Benzodiazepines Added To Schedule I
The fourth review cycle is the charm for Verrica's cantharidin topical solution; Rosemary Roberts, head of CDER's Counter-Terrorism and Emergency Coordination Staff, retires after 35 years at the FDA; DEA deems five designer benzodiazepines with no currently accepted medical use in the US as Schedule I controlled substances.
Verrica Finally Gets Molluscum Treatment To The Finish Line
Verrica’s Ycanth, a drug-device combination product containing a formulation of cantharidin, is approved by the FDA as the first treatment for molluscum, after three complete response letters.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice